{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,12]],"date-time":"2026-06-12T21:16:56Z","timestamp":1781299016810,"version":"3.54.1"},"reference-count":56,"publisher":"Elsevier BV","issue":"4-5","license":[{"start":{"date-parts":[[2017,10,1]],"date-time":"2017-10-01T00:00:00Z","timestamp":1506816000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2017,10,1]],"date-time":"2017-10-01T00:00:00Z","timestamp":1506816000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","eu-focus.europeanurology.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Urology Focus"],"published-print":{"date-parts":[[2017,10]]},"DOI":"10.1016\/j.euf.2017.11.008","type":"journal-article","created":{"date-parts":[[2017,11,26]],"date-time":"2017-11-26T21:03:51Z","timestamp":1511730231000},"page":"403-412","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":19,"title":["Immunotherapy in the Elderly"],"prefix":"10.1016","volume":"3","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9907-9112","authenticated-orcid":false,"given":"Aly-Khan A.","family":"Lalani","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dominick","family":"Boss\u00e9","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bradley A.","family":"McGregor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9201-3217","authenticated-orcid":false,"given":"Toni K.","family":"Choueiri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.euf.2017.11.008_bib0005","first-page":"537","article-title":"Aging, immunity, and cancer","volume":"11","author":"Fulop","year":"2011","journal-title":"Discov Med"},{"key":"10.1016\/j.euf.2017.11.008_bib0010","doi-asserted-by":"crossref","first-page":"1383","DOI":"10.1200\/JCO.2003.08.010","article-title":"Participation of patients 65 years of age or older in cancer clinical trials","volume":"21","author":"Lewis","year":"2003","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.euf.2017.11.008_bib0015","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1038\/nri2959","article-title":"Are senescence and exhaustion intertwined or unrelated processes that compromise immunity?","volume":"11","author":"Akbar","year":"2011","journal-title":"Nat Rev Immunol"},{"key":"10.1016\/j.euf.2017.11.008_bib0020","unstructured":"https:\/\/seer.cancer.gov\/statfacts\/html\/prost.htm"},{"key":"10.1016\/j.euf.2017.11.008_bib0025","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1200\/JCO.2016.69.1584","article-title":"Randomized, double-blind, phase III trial of ipilimumab versus placebo in asymptomatic or minimally symptomatic patients with metastatic chemotherapy-naive castration-resistant prostate cancer","volume":"35","author":"Beer","year":"2017","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.euf.2017.11.008_bib0030","doi-asserted-by":"crossref","first-page":"52810","DOI":"10.18632\/oncotarget.10547","article-title":"Early evidence of anti-PD-1 activity in enzalutamide-resistant prostate cancer","volume":"7","author":"Graff","year":"2016","journal-title":"Oncotarget"},{"key":"10.1016\/j.euf.2017.11.008_bib0035","unstructured":"National Cancer Institute. Cancer stat facts: bladder cancer. Surveillance, epidemiology, and end results program. https:\/\/seer.cancer.gov\/statfacts\/html\/urinb.html"},{"key":"10.1016\/j.euf.2017.11.008_bib0040","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/j.ctrv.2016.04.002","article-title":"Balancing treatment efficacy, toxicity and complication risk in elderly patients with metastatic renal cell carcinoma","volume":"46","author":"van den Brom","year":"2016","journal-title":"Cancer Treat Rev"},{"key":"10.1016\/j.euf.2017.11.008_bib0045","doi-asserted-by":"crossref","first-page":"804","DOI":"10.6004\/jnccn.2017.0100","article-title":"Kidney cancer, version 2.2017, NCCN clinical practice guidelines in oncology","volume":"15","author":"Motzer","year":"2017","journal-title":"J Natl Compr Cancer Netw"},{"key":"10.1016\/j.euf.2017.11.008_bib0050","doi-asserted-by":"crossref","first-page":"1803","DOI":"10.1056\/NEJMoa1510665","article-title":"Nivolumab versus everolimus in advanced renal-cell carcinoma","volume":"373","author":"Motzer","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.euf.2017.11.008_bib0055","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1016\/j.ijsu.2010.02.007","article-title":"Preferred Reporting Items for Systematic Reviews and Meta-analyses: the PRISMA statement","volume":"8","author":"Moher","year":"2010","journal-title":"Int J Surg"},{"key":"10.1016\/j.euf.2017.11.008_bib0060","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1056\/NEJMoa1001294","article-title":"Sipuleucel-T immunotherapy for castration-resistant prostate cancer","volume":"363","author":"Kantoff","year":"2010","journal-title":"N Engl J Med"},{"key":"10.1016\/j.euf.2017.11.008_bib0065","doi-asserted-by":"crossref","first-page":"3862","DOI":"10.1158\/1078-0432.CCR-15-0079","article-title":"A randomized phase II trial of sipuleucel-T with concurrent versus sequential abiraterone acetate plus prednisone in metastatic castration-resistant prostate cancer","volume":"21","author":"Small","year":"2015","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.euf.2017.11.008_bib0070","doi-asserted-by":"crossref","first-page":"3670","DOI":"10.1002\/cncr.24429","article-title":"Integrated data from 2 randomized, double-blind, placebo-controlled, phase 3 trials of active cellular immunotherapy with sipuleucel-T in advanced prostate cancer","volume":"115","author":"Higano","year":"2009","journal-title":"Cancer"},{"key":"10.1016\/j.euf.2017.11.008_bib0075","doi-asserted-by":"crossref","first-page":"877","DOI":"10.1016\/j.juro.2011.04.070","article-title":"Integrated safety data from 4 randomized, double-blind, controlled trials of autologous cellular immunotherapy with sipuleucel-T in patients with prostate cancer","volume":"186","author":"Hall","year":"2011","journal-title":"J Urol"},{"key":"10.1016\/j.euf.2017.11.008_bib0080","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1038\/pcan.2014.21","article-title":"Time to disease-related pain and first opioid use in patients with metastatic castration-resistant prostate cancer treated with sipuleucel-T","volume":"17","author":"Small","year":"2014","journal-title":"Prostate Cancer Prostatic Dis"},{"key":"10.1016\/j.euf.2017.11.008_bib0085","doi-asserted-by":"crossref","first-page":"1063","DOI":"10.1158\/2326-6066.CIR-15-0006","article-title":"Survival outcomes of sipuleucel-T phase III studies: impact of control-arm cross-over to salvage immunotherapy","volume":"3","author":"George","year":"2015","journal-title":"Cancer Immunol Res"},{"key":"10.1016\/j.euf.2017.11.008_bib0090","doi-asserted-by":"crossref","first-page":"1099","DOI":"10.1200\/JCO.2009.25.0597","article-title":"Overall survival analysis of a phase II randomized controlled trial of a Poxviral-based PSA-targeted immunotherapy in metastatic castration-resistant prostate cancer","volume":"28","author":"Kantoff","year":"2010","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.euf.2017.11.008_bib0095","unstructured":"Bavarian-Nordic. Independent Data Monitoring Committee recommends discontinuation of Bavarian Nordic\u2019s phase 3 study of PROSTVAC in metastatic prostate cancer."},{"key":"10.1016\/j.euf.2017.11.008_bib0100","doi-asserted-by":"crossref","first-page":"1260","DOI":"10.1158\/1078-0432.CCR-05-2059","article-title":"A randomized phase II study of concurrent docetaxel plus vaccine versus vaccine alone in metastatic androgen-independent prostate cancer","volume":"12","author":"Arlen","year":"2006","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.euf.2017.11.008_bib0105","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1046\/j.1464-410x.2001.02306.x","article-title":"A systematic review of intravesical bacillus Calmette-Guerin plus transurethral resection vs transurethral resection alone in Ta and T1 bladder cancer","volume":"88","author":"Shelley","year":"2001","journal-title":"BJU Int"},{"key":"10.1016\/j.euf.2017.11.008_bib0110","doi-asserted-by":"crossref","first-page":"1216","DOI":"10.1016\/j.urology.2005.12.014","article-title":"Can intravesical bacillus Calmette-Gu\u00e9rin reduce recurrence in patients with superficial bladder cancer? A meta-analysis of randomized trials","volume":"67","author":"Han","year":"2006","journal-title":"Urology"},{"key":"10.1016\/j.euf.2017.11.008_bib0115","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1016\/S0022-5347(05)64043-8","article-title":"Intravesical bacillus Calmette-Guerin versus mitomycin C for superficial bladder cancer: a formal meta-analysis of comparative studies on recurrence and toxicity","volume":"169","author":"B\u00f6hle","year":"2003","journal-title":"J Urol"},{"key":"10.1016\/j.euf.2017.11.008_bib0120","doi-asserted-by":"crossref","first-page":"1964","DOI":"10.1016\/S0022-5347(05)64273-5","article-title":"Intravesical bacillus Calmette-Guerin reduces the risk of progression in patients with superficial bladder cancer: a meta-analysis of the published results of randomized clinical trials","volume":"168","author":"Sylvester","year":"2002","journal-title":"J Urol"},{"key":"10.1016\/j.euf.2017.11.008_bib0125","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1016\/j.eururo.2009.04.038","article-title":"An individual patient data meta-analysis of the long-term outcome of randomised studies comparing intravesical mitomycin C versus bacillus Calmette-Gu\u00f6rin for non-muscle-invasive bladder cancer","volume":"56","author":"Malmstr\u00f6m","year":"2009","journal-title":"Eur Urol"},{"key":"10.1016\/j.euf.2017.11.008_bib0130","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1016\/j.eururo.2014.06.040","article-title":"Prognostic factors and risk groups in T1G3 non\u2013muscle-invasive bladder cancer patients initially treated with bacillus Calmette-Gu\u00e9rin: results of a retrospective multicenter study of 2451 patients","volume":"67","author":"Gontero","year":"2015","journal-title":"Eur Urol"},{"key":"10.1016\/j.euf.2017.11.008_bib0135","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/j.urology.2007.03.024","article-title":"Age and outcome of superficial bladder cancer treated with bacille Calmette-Guerin therapy","volume":"70","author":"Herr","year":"2007","journal-title":"Urology"},{"key":"10.1016\/j.euf.2017.11.008_bib0140","doi-asserted-by":"crossref","first-page":"694","DOI":"10.1016\/j.eururo.2014.05.033","article-title":"The effect of age on the efficacy of maintenance bacillus Calmette-Guerin relative to maintenance epirubicin in patients with stage Ta T1 urothelial bladder cancer: results from EORTC genito-urinary group study 30911","volume":"66","author":"Oddens","year":"2014","journal-title":"Eur Urol"},{"key":"10.1016\/j.euf.2017.11.008_bib0145","doi-asserted-by":"crossref","unstructured":"Balar AV, Castellano D, O\u2019Donnell PH, et al. First-line pembrolizumab in cisplatin-ineligible patients with locally advanced and unresectable or metastatic urothelial cancer (KEYNOTE-052): a multicentre, single-arm, phase 2 study. Lancet Oncol In press; 18 (11) 1483-1492 https:\/\/doi.org\/10.1016\/S1470-2045(17)30616-2","DOI":"10.1016\/S1470-2045(17)30616-2"},{"key":"10.1016\/j.euf.2017.11.008_bib0150","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/S0140-6736(16)32455-2","article-title":"Atezolizumab as first-line treatment in cisplatin-ineligible patients with locally advanced and metastatic urothelial carcinoma: a single-arm, multicentre, phase 2 trial","volume":"389","author":"Balar","year":"2017","journal-title":"Lancet"},{"key":"10.1016\/j.euf.2017.11.008_bib0155","doi-asserted-by":"crossref","first-page":"1015","DOI":"10.1056\/NEJMoa1613683","article-title":"Pembrolizumab as second-line therapy for advanced urothelial carcinoma","volume":"376","author":"Bellmunt","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.euf.2017.11.008_bib0160","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1016\/S1470-2045(17)30065-7","article-title":"Nivolumab in metastatic urothelial carcinoma after platinum therapy (CheckMate 275): a multicentre, single-arm, phase 2 trial","volume":"18","author":"Sharma","year":"2017","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.euf.2017.11.008_bib0165","doi-asserted-by":"crossref","first-page":"1590","DOI":"10.1016\/S1470-2045(16)30496-X","article-title":"Nivolumab monotherapy in recurrent metastatic urothelial carcinoma (CheckMate 032): a multicentre, open-label, two-stage, multi-arm, phase 1\/2 trial","volume":"17","author":"Sharma","year":"2016","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.euf.2017.11.008_bib0170","doi-asserted-by":"crossref","DOI":"10.1001\/jamaoncol.2017.2411","article-title":"Efficacy and safety of durvalumab in locally advanced or metastatic urothelial carcinoma: updated results from a phase 1\/2 open-label study","volume":"3","author":"Powles","year":"2017","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.euf.2017.11.008_bib0175","doi-asserted-by":"crossref","first-page":"2117","DOI":"10.1200\/JCO.2016.71.6795","article-title":"Avelumab, an anti-programmed death-ligand 1 antibody, in patients with refractory metastatic urothelial carcinoma: results from a multicenter, phase Ib study","volume":"35","author":"Apolo","year":"2017","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.euf.2017.11.008_bib0180","doi-asserted-by":"crossref","first-page":"1909","DOI":"10.1016\/S0140-6736(16)00561-4","article-title":"Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial","volume":"387","author":"Rosenberg","year":"2016","journal-title":"Lancet"},{"key":"10.1016\/j.euf.2017.11.008_bib0185","unstructured":"Genentech. Genentech provides update on phase III study of TECENTRIQ (atezolizumab) in people with previously treated advanced bladder cancer. Business Wire, 2017."},{"key":"10.1016\/j.euf.2017.11.008_bib0190","doi-asserted-by":"crossref","first-page":"2861","DOI":"10.1158\/1078-0432.CCR-10-0569","article-title":"Preoperative CTLA-4 blockade: tolerability and immune monitoring in the setting of a presurgical clinical trial","volume":"16","author":"Carthon","year":"2010","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.euf.2017.11.008_bib0195","doi-asserted-by":"crossref","first-page":"2271","DOI":"10.1056\/NEJMoa066838","article-title":"Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma","volume":"356","author":"Hudes","year":"2007","journal-title":"N Engl J Med"},{"key":"10.1016\/j.euf.2017.11.008_bib0200","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1056\/NEJMoa065044","article-title":"Sunitinib versus interferon alfa in metastatic renal-cell carcinoma","volume":"356","author":"Motzer","year":"2007","journal-title":"N Engl J Med"},{"key":"10.1016\/j.euf.2017.11.008_bib0205","doi-asserted-by":"crossref","first-page":"2103","DOI":"10.1016\/S0140-6736(07)61904-7","article-title":"Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial","volume":"370","author":"Escudier","year":"2007","journal-title":"Lancet"},{"key":"10.1016\/j.euf.2017.11.008_bib0210","doi-asserted-by":"crossref","first-page":"2137","DOI":"10.1200\/JCO.2009.26.5561","article-title":"Phase III trial of bevacizumab plus interferon alfa versus interferon alfa monotherapy in patients with metastatic renal cell carcinoma: final results of CALGB 90206","volume":"28","author":"Rini","year":"2010","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.euf.2017.11.008_bib0215","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1016\/S1470-2045(11)70124-3","article-title":"Temsirolimus and bevacizumab, or sunitinib, or interferon alfa and bevacizumab for patients with advanced renal cell carcinoma (TORAVA): a randomised phase 2 trial","volume":"12","author":"Negrier","year":"2011","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.euf.2017.11.008_bib0220","doi-asserted-by":"crossref","first-page":"688","DOI":"10.1200\/JCO.1995.13.3.688","article-title":"Results of treatment of 255 patients with metastatic renal cell carcinoma who received high-dose recombinant interleukin-2 therapy","volume":"13","author":"Fyfe","year":"1995","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.euf.2017.11.008_bib0225","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1038\/bjc.1992.152","article-title":"Intravenous interleukin-2 in patients over with metastatic renal carcinoma","volume":"65","author":"Negrier","year":"1992","journal-title":"Br J Cancer"},{"key":"10.1016\/j.euf.2017.11.008_bib0230","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1159\/000342764","article-title":"Clinical and safety profile of high-dose interleukin-2 treatment in elderly patients with metastatic melanoma and renal cell carcinoma","volume":"84","author":"Clark","year":"2013","journal-title":"Oncology"},{"key":"10.1016\/j.euf.2017.11.008_bib0235","doi-asserted-by":"crossref","first-page":"5539","DOI":"10.1158\/1078-0432.CCR-10-2082","article-title":"Vaccination of metastatic renal cancer patients with MVA-5T4: a randomized, double-blind, placebo-controlled phase III study","volume":"16","author":"Amato","year":"2010","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.euf.2017.11.008_bib0240","doi-asserted-by":"crossref","first-page":"1599","DOI":"10.1016\/S1470-2045(16)30408-9","article-title":"IMA901, a multipeptide cancer vaccine, plus sunitinib versus sunitinib alone, as first-line therapy for advanced or metastatic renal cell carcinoma (IMPRINT): a multicentre, open-label, randomised, controlled, phase 3 trial","volume":"17","author":"Rini","year":"2016","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.euf.2017.11.008_bib0245","doi-asserted-by":"crossref","unstructured":"Figlin R. Interim analysis of the phase 3 ADAPT trial evaluating rocapuldencel T (AGS-003), an individualized immunotherapy for the treatment of newly-diagnosed patients with metastatic renal cell carcinoma (mRCC). ESMO Congress, Madrid, Spain, 2017.","DOI":"10.1093\/annonc\/mdx376.003"},{"key":"10.1016\/j.euf.2017.11.008_bib0250","doi-asserted-by":"crossref","first-page":"994","DOI":"10.1016\/S1470-2045(16)30125-5","article-title":"Quality of life in patients with advanced renal cell carcinoma given nivolumab versus everolimus in CheckMate 025: a randomised, open-label, phase 3 trial","volume":"17","author":"Cella","year":"2016","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.euf.2017.11.008_bib0255","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1097\/CJI.0b013e318156e47e","article-title":"Ipilimumab (anti-CTLA4 antibody) causes regression of metastatic renal cell cancer associated with enteritis and hypophysitis","volume":"30","author":"Yang","year":"2007","journal-title":"J Immunother"},{"key":"10.1016\/j.euf.2017.11.008_bib0260","doi-asserted-by":"crossref","first-page":"1484","DOI":"10.1093\/annonc\/mdx151","article-title":"Immune checkpoint inhibitors in advanced renal cell carcinoma: experience to date and future directions","volume":"28","author":"Atkins","year":"2017","journal-title":"Ann Oncol"},{"key":"10.1016\/j.euf.2017.11.008_bib0265","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1007\/s40266-017-0479-1","article-title":"Cancer immunotherapies: are they as effective in the elderly?","volume":"34","author":"Poropatich","year":"2017","journal-title":"Drugs Aging"},{"key":"10.1016\/j.euf.2017.11.008_bib0270","doi-asserted-by":"crossref","unstructured":"Bilen MA, Hess KR, Subudhi SK, et al. Clinical predictors of survival in patients with castration-resistant prostate cancer receiving sipuleucel-T cellular immunotherapy. Cancer Chemother Pharmacol. In press; 80 (3) 583-589 https:\/\/doi.org\/10.1007\/s00280-017-3391-9","DOI":"10.1007\/s00280-017-3391-9"},{"key":"10.1016\/j.euf.2017.11.008_bib0275","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pgen.1006477","article-title":"Gene expression differences in prostate cancers between young and old men","volume":"12","author":"Ding","year":"2016","journal-title":"PLoS Genet"},{"key":"10.1016\/j.euf.2017.11.008_bib0280","doi-asserted-by":"crossref","first-page":"1928","DOI":"10.1200\/JCO.2000.18.9.1928","article-title":"Effect of cytokine therapy on survival for patients with advanced renal cell carcinoma","volume":"18","author":"Motzer","year":"2000","journal-title":"J Clin Oncol"}],"container-title":["European Urology Focus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S240545691730264X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S240545691730264X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,7]],"date-time":"2025-11-07T06:46:44Z","timestamp":1762498004000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S240545691730264X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,10]]},"references-count":56,"journal-issue":{"issue":"4-5","published-print":{"date-parts":[[2017,10]]}},"alternative-id":["S240545691730264X"],"URL":"https:\/\/doi.org\/10.1016\/j.euf.2017.11.008","relation":{},"ISSN":["2405-4569"],"issn-type":[{"value":"2405-4569","type":"print"}],"subject":[],"published":{"date-parts":[[2017,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Immunotherapy in the Elderly","name":"articletitle","label":"Article Title"},{"value":"European Urology Focus","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.euf.2017.11.008","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 European Association of Urology. Published by Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}